Average Diluted Shares Outstanding: 243 million, 1% lower than a year ago. Cardinal Health Inc (NYSE:CAH) reported strong second quarter results, driven by robust demand in pharmaceutical and ...

Cardinal Health, Inc. CAH reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.93, which beat the Zacks Consensus Estimate of $1.75 by 10.3%. The bottom line also improved 2 ...

Maria is best known for her work on steroid 21-hydroxylase deficiency, the most common form of congenital adrenal hyperplasia (CAH). Most of her fellows and trainees in the late 1970s and early 1980s ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Cardinal Health (CAH) reports results for the quarter ended December 2024. While this widely-known consensus outlook ...

related to benign prostatic hyperplasia. Materials and methods: In this open-label trial, 12 male patients (median age 67 years) with an I-PSS >15 (median 16) and maximum urinary flow (Q max ...

One company to watch right now is Cardinal Health (CAH). CAH is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock has a Forward P/E ratio of 15.28. This compares to its ...

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, announced positive topline results from an open-label, phase 2 congenital adrenal hyperplasia (CAH) study of investigational ...

Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. For more information about the Phase 2 TouCAHn study in classic CAH, please visit ...

Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. For more information about the Phase 2 TouCAHn study in classic CAH, please visit ...

While Spruce Biosciences Inc.’s tildacerfont missed its phase II primary endpoint in classic congenital adrenal hyperplasia (CAH) last March, the U.S. FDA approved Crenessity (crinecerfont) from ...

At University of Utah Health, our urologists provide the full spectrum of treatment for men with an enlarged prostate — also known as benign prostatic hyperplasia (BPH). Our highly trained specialists ...